Thursday, 1. September 2022 | Filed under Company News

InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer

— Seasoned professional with more than 8 years of healthcare corporate finance experience

InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it has appointed Mrs. Nicole Witzmann as Chief Financial Officer (CFO) effective September 1, 2022.

Read more…

Thursday, 4. August 2022 | Filed under Company News

BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants

— Resorbable implants to treat pectus excavatum and silicone breast implant revision / congenital defect correction

— First patients treated in Australia

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced the start of two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia.

Read more…

Wednesday, 27. July 2022 | Filed under Company News

ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories



HypoxE® Test allows for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) caused by lack of oxygen during birth

— ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers

ELITechGroup and InfanDx AG today announced at the ongoing 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL, USA, the signing of a Memorandum of Understanding (MoU) to collaborate on the development and manufacturing of InfanDx’ HypoxE® Test for ELITechGroup’s family of Selectra Pro clinical chemistry analyzers. The parties intend to enter into a formal collaboration agreement once the biomarkers targeted by InfanDx’ HypoxE® Test are validated in patients from the recently closed BANON cohort study. This final validation is expected by the end of Q3-2022.

Read more…